SEC Filing Summary: Revelation Biosciences, Inc. (REVB)
Business Context and Reporting Period
This Form 8-K Current Report, dated May 28, 2025, details a registered public offering of securities by Revelation Biosciences, Inc. The offering closed on May 29, 2025. The Company is a Delaware corporation headquartered in San Diego, California, with common stock and warrants trading on The Nasdaq Stock Market LLC.
Key Financial Metrics and Transaction Details
The filing reports the following specific financial data related to the capital raise:
- Gross Proceeds: Approximately $4.0 million.
- Securities Issued:
- 675,000 shares of Common Stock.
- 2,965,000 Pre-Funded Warrants (exercised immediately post-closing).
- 14,560,000 Class H Common Stock Warrants.
- Offering Price: $1.10 per share of Common Stock (and associated warrants) or $1.09 per Pre-Funded Warrant (and associated warrants).
- Transaction Costs: An 8% cash fee paid to the Placement Agent (Roth Capital Partners, LLC) plus reimbursement of expenses and legal fees.
The filing does not provide current revenue, profit, cash flow, operating margins, total debt, or liquidity metrics outside of the proceeds from this specific transaction.
Material Changes and Terms
The primary material change is the dilution of existing shareholders due to the issuance of new equity and warrants. Key terms include:
- Warrant Terms: Class H Warrants have an exercise price of $1.10, are exercisable immediately, and expire five years from issuance. The exercise price is subject to reduction in the event of future dilutive issuances or reverse stock splits.
- Pre-Funded Warrants: These have an exercise price of $0.0001, do not expire, and were issued to purchasers to avoid beneficial ownership exceeding 4.99% (or 9.99% at election).
- Lock-Up Agreement: The Company and its executive officers and directors agreed not to offer, sell, or transfer securities for 90 days following the closing date, subject to limited exceptions.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard representations and warranties customary for such transactions. The proceeds are intended to fund the Company's operations, though specific allocation is not detailed in this text. The transaction was executed pursuant to a Registration Statement on Form S-1 declared effective on May 28, 2025.
Key Facts for Investor Verification
- Verify the total number of outstanding shares post-closing to assess the dilution impact of the 3.64 million new shares (675,000 common + 2,965,000 from pre-funded warrants) and 14.56 million warrants.
- Confirm the net proceeds after deducting the 8% placement fee and other transaction expenses.
- Review the Company's cash position and burn rate to determine the runway provided by the $4.0 million gross proceeds.
- Monitor the 90-day lock-up expiration date for potential selling pressure from insiders.
- Check for any subsequent dilutive issuances that would trigger the anti-dilution adjustment on the Class H Warrants.